JP2012036225A5 - - Google Patents

Download PDF

Info

Publication number
JP2012036225A5
JP2012036225A5 JP2011253859A JP2011253859A JP2012036225A5 JP 2012036225 A5 JP2012036225 A5 JP 2012036225A5 JP 2011253859 A JP2011253859 A JP 2011253859A JP 2011253859 A JP2011253859 A JP 2011253859A JP 2012036225 A5 JP2012036225 A5 JP 2012036225A5
Authority
JP
Japan
Prior art keywords
vla
composition
binding antibody
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011253859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012036225A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012036225A publication Critical patent/JP2012036225A/ja
Publication of JP2012036225A5 publication Critical patent/JP2012036225A5/ja
Withdrawn legal-status Critical Current

Links

JP2011253859A 2004-08-20 2011-11-21 多発性硬化症の長期処置 Withdrawn JP2012036225A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US60346804P 2004-08-20 2004-08-20
US60347004P 2004-08-20 2004-08-20
US60349504P 2004-08-20 2004-08-20
US60/603,470 2004-08-20
US60/603,495 2004-08-20
US60/603,468 2004-08-20
US61602304P 2004-10-05 2004-10-05
US60/616,023 2004-10-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007528011A Division JP2008510714A (ja) 2004-08-20 2005-08-18 多発性硬化症の長期処置

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012001065A Division JP2012067139A (ja) 2004-08-20 2012-01-06 多発性硬化症の長期処置
JP2014252699A Division JP2015052022A (ja) 2004-08-20 2014-12-15 多発性硬化症の長期処置

Publications (2)

Publication Number Publication Date
JP2012036225A JP2012036225A (ja) 2012-02-23
JP2012036225A5 true JP2012036225A5 (https=) 2012-04-12

Family

ID=35968170

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007528011A Withdrawn JP2008510714A (ja) 2004-08-20 2005-08-18 多発性硬化症の長期処置
JP2011253859A Withdrawn JP2012036225A (ja) 2004-08-20 2011-11-21 多発性硬化症の長期処置
JP2012001065A Pending JP2012067139A (ja) 2004-08-20 2012-01-06 多発性硬化症の長期処置
JP2014252699A Pending JP2015052022A (ja) 2004-08-20 2014-12-15 多発性硬化症の長期処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007528011A Withdrawn JP2008510714A (ja) 2004-08-20 2005-08-18 多発性硬化症の長期処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012001065A Pending JP2012067139A (ja) 2004-08-20 2012-01-06 多発性硬化症の長期処置
JP2014252699A Pending JP2015052022A (ja) 2004-08-20 2014-12-15 多発性硬化症の長期処置

Country Status (6)

Country Link
US (5) US20080260728A1 (https=)
EP (2) EP1789086A4 (https=)
JP (4) JP2008510714A (https=)
AU (1) AU2005277343B2 (https=)
CA (2) CA2478458A1 (https=)
WO (4) WO2006023629A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
JP4871355B2 (ja) 2005-05-12 2012-02-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 無線メッシュネットワークのための分散型学習方法
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
MX2008011176A (es) * 2006-03-03 2008-09-10 Elan Pharm Inc Metodos para tratar padecimientos inflamatorios y autoinmunes con natalizumab.
WO2008103378A2 (en) * 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
NZ595526A (en) 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
CN102906278A (zh) 2010-01-11 2013-01-30 比奥根艾迪克Ma公司 用于jc病毒抗体的测定
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
HRP20171045T1 (hr) 2010-04-16 2017-10-06 Biogen Ma Inc. Protutijela anti-vla-4
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2713724A4 (en) * 2011-05-26 2015-03-11 Biogen Idec Inc METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT
DK2715352T3 (da) 2011-05-31 2019-05-20 Biogen Ma Inc Fremgangsmåde til vurdering af risiko for pml
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP5711167B2 (ja) 2012-02-22 2015-04-30 三ツ星ベルト株式会社 アラミド心線及び伝動ベルト
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
HU196394B (en) * 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69309487T2 (de) * 1992-11-13 1997-10-23 Univ Washington Peripheralisierung hämatopoietischer stammzellen
DE69419721T2 (de) * 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6432404B1 (en) * 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
AU2203199A (en) * 1997-12-30 1999-07-19 Bioabsorbable Concepts, Inc. Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system
US20040107368A1 (en) * 1998-06-04 2004-06-03 Z4 Technologies, Inc. Method for digital rights management including self activating/self authentication software
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US7194092B1 (en) * 1998-10-26 2007-03-20 Microsoft Corporation Key-based secure storage
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
EP1119368A2 (en) * 1999-03-03 2001-08-01 Biogen, Inc. Methods of modulating lipid metabolism and storage
WO2001045725A2 (en) * 1999-12-23 2001-06-28 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
WO2001075078A1 (en) * 2000-03-31 2001-10-11 The Scripps Research Institute HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DK1485127T3 (da) * 2002-02-25 2011-10-03 Elan Pharm Inc Anvendelse af midler til behandling af inflammation
WO2004035086A2 (en) * 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
CA2514117A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
DK2236154T3 (en) * 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
CA2563432A1 (en) * 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
WO2006026759A2 (en) * 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
EA013080B1 (ru) * 2005-06-09 2010-02-26 Юсб Фарма С.А. 2,6-хинолинильные производные, способы их получения и их применение
WO2007008943A2 (en) * 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists

Similar Documents

Publication Publication Date Title
JP2012036225A5 (https=)
JP2008510714A5 (https=)
JP2015529225A5 (https=)
JP2018184417A5 (https=)
JP2014533279A5 (https=)
JP2016518387A5 (https=)
RU2015112576A (ru) Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2
JP2023055871A5 (https=)
JP2012193216A5 (https=)
JP2015515475A5 (https=)
JP2017503820A5 (https=)
JP2015505564A5 (https=)
JP2009518441A5 (https=)
JP2015532292A5 (https=)
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
JP2016528247A5 (https=)
JP2013505205A5 (https=)
JP2017160178A5 (https=)
JP2017537105A5 (https=)
JP2013231087A5 (https=)
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2015517529A5 (https=)
JP2013516493A5 (https=)
RU2015134422A (ru) Применение левоцитиризина и монтелукаста при лечении васкулита
JP2017537927A5 (https=)